A recombinant vaccinia virus (rvv) expressing, human immunodeficiency virus type 1 (HIV-1) external envelope
glycoprotein, gp120, fused to a non-cleavable transmembrane
protein, vvE13, elicited protection against a tumor cell line expressing HIV-1 full length envelope
glycoprotein, gp160, in mice. Mice vaccinated with vvE13 exhibited a decreased incidence of
tumor development and significantly smaller
tumors in comparison to mice vaccinated with rvv gp160, vvE1, or a
thymidine kinase minus (TK-) rvv, vSC11, or
phosphate-buffered saline (PBS) injected controls. vvE13 and vvE1 also delayed
tumor development, compared to vSC11 and PBS-injected controls; however, a statistical correlation could not be demonstrated due to the development of
tumors in so few animals. Specificity toward HIV-1 envelope
glycoprotein, was shown, since HIV-1 envelope-
tumor prevention (incidence for vvE13 and size for vvE1 and vvE13 and delay for vvE1 and vvE13) was statistically superior with HIV-1 envelope expressing
tumors compared to parenteral
tumors. The vvE13 recombinant vaccinia virus expressing the HIV-1 envelope
glycoprotein gp120 fused to a non-cleavable transmembrane
protein elicits superior protection against
tumors expressing the gp160 envelope
glycoprotein, as compared to vvE1 expressing gp160.